Q-omics provides the consensus-scored SNX29 profile across patient tissues and cancer cell-line models. SNX29 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNX29 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SNX29 RNA expression shows 20,394 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where SNX29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX29 survival associations across molecular data types. SNX29 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX29 RNA expression–survival associations across cancer types. High SNX29 expression shows unfavorable associations in BLCA, MESO and LUSC, but favorable associations in KIRC, HNSC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNX29 RNA expression.
This table summarizes SNX29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SNX29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX29 shows lower tumor expression in THCA, KICH, LUSC and COAD and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher SNX29 RNA expression in normal versus tumor tissue (log2 FC = −0.867, t-test p < 0.001).
This table shows molecular features associated with SNX29 in patient tissues and cancer cell lines. In patient samples, SNX29 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
